AstraZeneca购买EsoBiotec 最多1B美元,用于推进癌症治疗技术。 AstraZeneca buys EsoBiotec for up to $1B to advance cancer treatment technology.

AstraZeneca同意以最多10亿美元的价格购买生物技术公司EsoBiotec, 目的是用ENABL平台实现癌症治疗革命。 AstraZeneca has agreed to buy biotech firm EsoBiotec for up to $1 billion, aiming to revolutionize cancer treatments with its ENaBL platform. 这种技术可以直接在病人身体内编程免疫细胞,从而有可能将治疗时间从几周缩短到几分钟。 This technology can program immune cells directly in the patient's body, potentially reducing treatment times from weeks to minutes. EsoBiotec将成为AstraZeneca的独资子公司,其收购预计将在2025年第二季度完成,等待监管批准。 EsoBiotec will become a wholly owned subsidiary of AstraZeneca, with the acquisition expected to complete in the second quarter of 2025, pending regulatory approval.